Isabel Ruiz-Camps
Overview
Explore the profile of Isabel Ruiz-Camps including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
991
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Monzo-Gallo P, Lopera C, Badia-Tejero A, Machado M, Garcia-Rodriguez J, Vidal-Cortes P, et al.
Int J Infect Dis
. 2024 Jul;
146:107188.
PMID: 39067149
No abstract available.
2.
Royo-Cebrecos C, Laporte-Amargos J, Pena M, Ruiz-Camps I, Garcia-Vidal C, Abdala E, et al.
Microorganisms
. 2024 Apr;
12(4).
PMID: 38674650
This large, multicenter, retrospective cohort study including onco-hematological neutropenic patients with bloodstream infection (PABSI) found that among 1213 episodes, 411 (33%) presented with septic shock. The presence of solid tumors...
3.
Monzo-Gallo P, Lopera C, Badia-Tejero A, Machado M, Garcia-Rodriguez J, Vidal-Cortes P, et al.
Int J Infect Dis
. 2024 Apr;
144:107070.
PMID: 38663477
Objectives: Information is scarce on clinical experiences with non-neutropenic patients with invasive fungal infection (IFI) receiving isavuconazole. We aimed to report the safety and effectiveness of this drug as a...
4.
Vincenzi B, Cortellini A, Mazzocca A, Orlando S, Romandini D, Aguilar-Company J, et al.
Ther Adv Med Oncol
. 2024 Jan;
16:17588359231225028.
PMID: 38249336
Background: To date, limited evidence exists on the impact of COVID-19 in patients with soft tissue sarcoma (STS), nor about the impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19...
5.
Mostaghim A, Minkove S, Aguilar-Company J, Ruiz-Camps I, Eremiev-Eremiev S, Dettorre G, et al.
Int J Infect Dis
. 2023 Nov;
139:13-20.
PMID: 38029831
Objectives: To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19. Methods: The OnCovid registry (NCT04393974) was...
6.
Medina I, Carpio C, Ruiz-Camps I, Albasanz-Puig A, Lopez-Godino O, Esperalba J, et al.
Immunotherapy
. 2023 Sep;
15(16):1369-1374.
PMID: 37718888
Chimeric antigen receptor (CAR) T cells targeting CD19 have changed the treatment landscape of patients with relapsed/refractory diffuse large B-cell lymphoma. Infections are one of the most frequent complications after...
7.
Ruiz-Camps I, Albasanz-Puig A
Transpl Infect Dis
. 2023 Jul;
25(5):e14106.
PMID: 37489801
No abstract available.
8.
Puerta-Alcalde P, Monzo-Gallo P, Aguilar-Guisado M, Ramos J, Laporte-Amargos J, Machado M, et al.
J Infect
. 2023 May;
87(1):46-53.
PMID: 37201859
Objectives: We describe the current epidemiology, causes, and outcomes of breakthrough invasive fungal infections (BtIFI) in patients with haematologic malignancies. Methods: BtIFI in patients with ≥ 7 days of prior...
9.
Jimenez M, Fernandez-Naval C, Navarro V, Novoa S, Martinez-Gallo M, Medina D, et al.
Am J Hematol
. 2023 May;
98(8):1204-1213.
PMID: 37151135
Data on the effect of booster SARS-CoV-2 vaccination are mainly focused on humoral immunogenicity, while the kinetics of vaccine-induced cellular response and its correlation with effectiveness in hematologic patients are...
10.
Cortellini A, Tabernero J, Mukherjee U, Salazar R, Sureda A, Maluquer C, et al.
Lancet Oncol
. 2023 Mar;
24(4):335-346.
PMID: 36898391
Background: COVID-19 sequelae can affect about 15% of patients with cancer who survive the acute phase of SARS-CoV-2 infection and can substantially impair their survival and continuity of oncological care....